GLP-1 medicines in New Zealand: what's approved, what they cost, and what's funded

The short version: several GLP-1 medicines are approved for weight management in New Zealand, none of them is publicly funded, and a month of treatment costs roughly $400–900 out of pocket depending on the medicine and dose. Pharmac has assessed Wegovy and put it on its funding wish-list with a high-priority recommendation — but with no application for Mounjaro for weight loss and no funding timeline for anything.

What's approved here

Approval and funding are different gates, run by different agencies. Medsafe decides whether a medicine can be sold in New Zealand at all; Pharmac decides whether the public pays for it.

• →Wegovy (semaglutide) — approved for weight management and available in NZ pharmacies on prescription.
• →Mounjaro (tirzepatide) — approved by Medsafe in December 2025 for type 2 diabetes and chronic weight management, available since early 2026. It targets two gut hormones (GLP-1 and GIP) rather than one.
• →Saxenda (liraglutide) — an older daily injection, approved for weight management.
• →Ozempic (semaglutide) — approved for type 2 diabetes, not for weight management, though the ingredient is the same as Wegovy's at different doses.

All of these are prescription medicines: a doctor or nurse practitioner has to assess you and prescribe them.

Where Pharmac funding stands

As of its last update (September 2026), Pharmac does not fund any GLP-1 medicine for weight management. The current position:

• →Wegovy sits on Pharmac's Options for Investment list — the list of medicines it would like to fund — after its obesity advisory group recommended it as a high priority.
• →The criteria discussed publicly would target funding narrowly: a BMI of 35 or more with at least two weight-related conditions, or a BMI over 50, with treatment stopped if weight loss is under 10% at six months.
• →Pharmac is also seeking clinical advice on Wegovy for people who have a heart condition.
• →No application has been made to fund Mounjaro for weight loss. A separate application for type 2 diabetes is being assessed.
• →Pharmac's own words: "We cannot say when, or if, any medicine will be funded."

Being on the Options for Investment list is a genuine step — it is not a decision, a budget line or a date. We untangle the three steps — approval, recommendation, funding — in Wegovy and Pharmac: where public funding actually stands.

What it actually costs

Because nothing is funded, people pay the full private price, which varies by pharmacy, medicine and dose. Reported ranges:

Add GP or telehealth consultation fees on top. Prices change — check with a pharmacy rather than relying on any article, including this one.

If you're prescribed one: what good care looks like

Whether one of these medicines is appropriate for you is a decision for a doctor or nurse practitioner, not for this guide. If you are prescribed one, the pattern of good care is consistent across the official guidance. Before starting: a proper history, covering your weight, your health conditions, the other medicines you take and any plans for pregnancy. During treatment: a plan for how side effects will be handled, and scheduled follow-up — a review of how you are getting on, what you are managing to eat, and how your weight and strength are changing — rather than a repeat script with no check-in. Side effects are worth reporting: tell your prescriber or pharmacist first, and anyone in New Zealand can also report a suspected reaction to CARM, the Centre for Adverse Reactions Monitoring that Medsafe uses to track medicine safety. And stay with legitimate supply: Medsafe has warned about unapproved "peptide" products sold through social media and overseas websites, which carry no quality assurance at all.

What we still don't know

Whether and when Pharmac will fund Wegovy; whether a Mounjaro weight-loss funding application will be made; and whether the new oral GLP-1 pills approved overseas in 2026 will be filed with Medsafe. We'll cover each of those the week it moves.